KMDA Kamada Ltd.
Kamada Ltd. (KMDA) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Kamada Ltd.
Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops and produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.